BSE Live
Apr 13, 16:01Prev. Close
2332.70
Open Price
2330.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 13, 15:55Prev. Close
2333.80
Open Price
2316.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2315.10 (249)
| Cash Flow of Lupin (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 4,837.12 | 2,784.69 | 527.14 | -161.53 | 1,629.70 | |
| Net CashFlow From Operating Activities | 2,444.65 | 2,504.13 | 1,793.99 | 151.03 | 1,570.08 | |
| Net Cash Used In Investing Activities | -1,766.32 | -1,599.02 | -1,269.17 | -371.79 | -2,507.52 | |
| Net Cash Used From Financing Activities | -460.23 | -867.07 | -498.26 | 102.45 | -53.17 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 218.10 | 38.04 | 26.56 | -118.31 | -990.61 | |
| Cash And Cash Equivalents Begin of Year | 123.70 | 85.66 | 59.10 | 177.41 | 1,168.02 | |
| Cash And Cash Equivalents End Of Year | 341.80 | 123.70 | 85.66 | 59.10 | 177.41 |
13.04.2026
09.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
12.11.2025
Lupin Standalone September 2025 Net Sales at Rs 4,068.28 crore, down 0.92% Y-o-Y
07.11.2025
Lupin Consolidated September 2025 Net Sales at Rs 7,047.51 crore, up 24.23% Y-o-Y
15.05.2025
Lupin Standalone March 2025 Net Sales at Rs 4,485.67 crore, up 32.09% Y-o-Y
28.02.2025
Lupin Consolidated December 2024 Net Sales at Rs 5,767.71 crore, up 10.97% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth